After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave the way for new treatment ... Aug. 22, 2024 — Managing hard ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectivelyMore than 3,500 ...